The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial - Takeaways - MDSpire

The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial

  • By

  • Qinggang Ge

  • Libo Zheng

  • Man Zhao

  • Chao Li

  • Zhiling Zhao

  • Zongyu Wang

  • Qiang Zhang

  • Mai Shi

  • Yuxuan Li

  • Jianan Zhang

  • Yixian Qiao

  • Senhao Wei

  • Ning Shen

  • Haomiao Long

  • Yongjun Liu

  • Jie Qiao

  • June 10, 2026

  • 0 min

Share

  • 1

    This Phase I trial evaluated the safety and preliminary efficacy of allogeneic human umbilical cord mesenchymal stem cells in ARDS patients.

  • 2

    Twelve patients with mild-to-moderate ARDS received a single intravenous infusion of BC-U001, with no severe adverse events reported.

  • 3

    The overall 28-day all-cause mortality rate was 8.3%, with no deaths among COVID-19-related ARDS patients.

  • 4

    Significant improvements in oxygenation and reductions in lung injury scores were observed in the middle dose group.

  • 5

    The trial supports further research on hUC-MSCs for ARDS, highlighting their safety and potential therapeutic effects.

Original Source(s)

The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial

  • by Qinggang Ge, Libo Zheng, Man Zhao, Chao Li, Zhiling Zhao, Zongyu Wang, Qiang Zhang, Mai Shi, Yuxuan Li, Jianan Zhang, Yixian Qiao, Senhao Wei, Ning Shen, Haomiao Long, Yongjun Liu, Jie Qiao

  • June 10, 2026

Related Content

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min
Psychiatric events induced by roflumilast: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System database

Correction: Case Report: PD-1/CTLA-4 dual checkpoint blockade(QL1706) in advanced pulmonary squamous cell carcinoma complicated by multidrug-resistant tuberculosis after multiple lines of immunotherapy